Guardant Health (GH) to Release Earnings on Thursday

Key Points

• Guardant Health will report Q1 2026 results after the market close on Thursday, May 7, with analysts expecting EPS of ($0.47) and revenue of about $279.17 million; the earnings call is scheduled for 4:30 PM ET.
• In the prior quarter (reported Feb. 19) the company missed EPS (−$0.50 vs. est. −$0.43) but beat revenue at $281.27 million, a 39.4% year‑over‑year increase.
• GH shares trade near $83.41 (52‑week range $36.36–$120.74) and carry a consensus "Moderate Buy" from analysts (20 Buys, 1 Hold, 1 Sell) with an average price target of $125.20.

Guardant Health (NASDAQ:GH - Get Free Report) will likely be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.47) per share and revenue of $279.1740 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. During the same period in the previous year, the company posted ($0.62) earnings per share. The business's quarterly revenue was up 39.4% on a year-over-year basis. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Guardant Health Stock Performance

Shares of GH stock opened at $83.41 on Thursday. Guardant Health has a fifty-two week low of $36.36 and a fifty-two week high of $120.74. The firm has a market capitalization of $10.94 billion, a price-to-earnings ratio of -25.20 and a beta of 1.64. The stock's 50-day simple moving average is $89.69 and its 200-day simple moving average is $95.97.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares in the company, valued at approximately $1,945,353.20. This represents a 15.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the sale, the director owned 1,193 shares of the company's stock, valued at approximately $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,596 shares of company stock worth $775,767 in the last 90 days. Corporate insiders own 6.10% of the company's stock.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently added to or reduced their stakes in the business. Xponance LLC raised its stake in shares of Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company's stock valued at $984,000 after buying an additional 199 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock worth $36,000 after buying an additional 219 shares during the last quarter. Wealthspire Advisors LLC boosted its stake in shares of Guardant Health by 6.4% in the fourth quarter. Wealthspire Advisors LLC now owns 3,886 shares of the company's stock worth $397,000 after buying an additional 235 shares during the last quarter. Arax Advisory Partners grew its holdings in Guardant Health by 61.5% during the fourth quarter. Arax Advisory Partners now owns 733 shares of the company's stock worth $75,000 after acquiring an additional 279 shares during the period. Finally, Commonwealth Equity Services LLC raised its position in Guardant Health by 5.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,546 shares of the company's stock valued at $669,000 after acquiring an additional 354 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on GH. Guggenheim lifted their target price on shares of Guardant Health from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Robert W. Baird began coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an "outperform" rating and a $120.00 price target on the stock. Wells Fargo & Company raised their price target on shares of Guardant Health from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, February 20th. BTIG Research lifted their price objective on shares of Guardant Health from $140.00 to $145.00 and gave the stock a "buy" rating in a research note on Friday, February 20th. Finally, Mizuho set a $135.00 price objective on shares of Guardant Health in a report on Friday, January 9th. Twenty analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $125.20.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.